BURLINGTON, ON, July 23,
2024 /CNW/ - Boehringer Ingelheim Canada's bold and
innovative national program, Access for Health Education and
Disease Management (AHEAD), is addressing critical gaps in
Canada's health system for people
living with type 2 diabetes (T2D) and heart failure (HF).
AHEAD aims to transform the support provided by allied health
professionals to patients with T2D and HF. With 58 programs running
within primary and specialty care clinics across Canada, the program focuses on both in-person
and remote care, enhancing the healthcare team's efforts to
optimize disease management. By incorporating guideline directed
medical therapy, improving patient understanding of their
conditions and self-management strategies, AHEAD aims to improve
health outcomes, streamline patient flow within clinical practices,
reduce re-hospitalizations and minimize emergency department (ED)
visits.
The program, which began in 2023, has demonstrated a positive
impact for patients. In its year of inception, AHEAD potentially
benefited more than 4,200 patients. Based on the allied healthcare
professionals reporting, 67 per cent of patients required
medication optimization, 86 per cent required disease knowledge
improvement and 78 per cent were identified with cardiovascular
risk illustrating a gap in the system and the need for support. In
addition, 100 per cent of allied health professionals who
participated in the program would recommend the program to other
allied health and healthcare professionals.
"Thanks to the AHEAD program funding, I have been able to
significantly enhance support for patients, leading to improved
outcomes and better quality of life. This investment was crucial to
provide tailored, effective care that makes a tangible difference
in patients' health journeys." – Noah
Hatch, Pharmacist, Edmonton.
Alberta.
AHEAD also tackles significant health system challenges, such as
equity issues related to language, cultural considerations, and
accessibility, particularly in remote areas. Allied health
educators proficient in multiple languages and trained in specific
cultural cuisine support the program. These educators are also
equipped to provide virtual management, significantly enhancing
accessibility for patients across diverse demographics.
"Boehringer Ingelheim Canada is committed to delivering
innovative and customized solutions to promote better health
outcomes and sustainable patient care," says Annie Beauchemin, Head of Market Access,
Boehringer Ingelheim Canada. "The success of the AHEAD program
demonstrates our dedication to addressing critical gaps in the
healthcare system and supporting people living with type 2 diabetes
and heart failure across the country. By leveraging innovative
solutions and collaborating with allied healthcare professionals,
we strive to make a meaningful impact for patients."
About Boehringer Ingelheim (Canada) Ltd.
Boehringer Ingelheim is a biopharmaceutical company active in both
human and animal health. As one of the industry's top investors in
research and development, the company focuses on developing
innovative therapies that can improve and extend lives in areas of
high unmet medical need. Independent since its foundation in 1885,
Boehringer takes a long-term perspective, embedding sustainability
along the entire value chain. More than 53,500 employees serve over
130 markets to build a healthier, more sustainable, and equitable
tomorrow. The Canadian headquarters of Boehringer Ingelheim was
established in 1972 in Montreal,
Quebec and is now located in Burlington, Ontario. Boehringer Ingelheim
employs approximately 500 people across Canada. Learn more at
www.boehringer-ingelheim.com/ca.
SOURCE Boehringer Ingelheim Canada Ltd.